Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Monotherapy for Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck
ChiCTR2100047475Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in salivary gland cancer (SGC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Disease control rate (DCR). Started May 2020; status: recruiting.
02
Drugs
anlotinib
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on ChiCTR2100047475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047475.